Quantcast
Home > Quotes > CNST

Constellation Pharmaceuticals, Inc. Common Stock (CNST) Quote & Summary Data

CNST 
$5.736
*  
0.001
0.02%
Get CNST Alerts
*Delayed - data as of Nov. 19, 2018 13:01 ET  -  Find a broker to begin trading CNST now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CNST Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.70 / $ 5.80
1 Year Target
20
Today's High / Low
$ 5.8999 / $ 5.69
Share Volume
5,633
50 Day Avg. Daily Volume
46,176
Previous Close
$ 5.735
52 Week High / Low
$ 12.21 / $ 5.57
Market Cap
147,523,209
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
5,633
50 Day Avg. Daily Volume:
46,176

Trading Range

The current last sale of $5.736 is 2.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.8999 $ 12.21
 Low: $ 5.69 $ 5.57

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company using our expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Platform insights and clinical experience guide development of our wholly owned lead product candidates: CPI-1205 which inhibits enhancer of zeste homolog 2, or EZH2, and CPI-0610 which inhibits bromodomain and extra terminal domain, or BET, proteins. We believe that our approach to targeting these central gene regulatory mechanisms associated with cancer proliferation may enable us to provide therapeutic benefits to cancer patients.  ... More ...  


Risk Grade

Where does CNST fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.69
Open Date:
Nov. 19, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x